Article Text

Download PDFPDF
Fexofenadine inhibits TNF signaling through targeting to cytosolic phospholipase A2 and is therapeutic against inflammatory arthritis
  1. Ronghan Liu1,
  2. Yuehong Chen1,
  3. Wenyu Fu1,
  4. Shuya Wang1,
  5. Yazhou Cui1,
  6. Xiangli Zhao1,
  7. Zi-Ning Lei2,
  8. Aubryanna Hettinghouse1,
  9. Jody Liu1,
  10. Chao Wang1,
  11. Chen Zhang1,
  12. Yufei Bi1,
  13. Guozhi Xiao3,
  14. Zhe-Sheng Chen2,
  15. Chuan-ju Liu1,4
  1. 1Department of Orthopaedic Surgery, New York University Medical Center, New York City, New York, USA
  2. 2Department of Pharmaceutical Science, College ofPharmacy and Health Sciences, St. John’s University, New York, NY, USA
  3. 3Department of Orthopedic Surgery, Rush University Medical Center, Chicago, IL, USA
  4. 4Departmentof Cell Biology, New York University School of Medicine, New York, NY, USA
  1. Correspondence to Dr Chuan-ju Liu, Rm 1608, HJD, Department of Orthopaedic Surgery, New York University Medical Center, 301 East 17th Street, New York NY10003, USA; chuanju.liu{at}nyumc.org

Footnotes

  • RL and YC contributed equally.

  • Handling editor Josef S Smolen

  • Contributors RL and YC designed and performed experiments, collected and analysed data, and cowrote the paper. YC participated in the design of the experiments and analysis of the data, particularly the identification and characterisation of the drug target. WF, SW, XZ, AH, JL, L. Zhang, CW, CZ and YB assisted with experiments, and collected and analysed data. ZL and Z-SC performed the IFD and MD simulations, and also assisted in editing the manuscript. GX assisted in analysing the data and editing the manuscript. CL designed and supervised this study, analysed data, and wrote and edited the manuscript.

  • Funding This work was supported partly by NIH research grants R01AR062207, R01AR061484, R01NS103931 and a DOD research grant W81XWH-16-1-0482.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Ethics approval All animal studies were performed in accordance with institutional guidelines and with approval from the Institutional Animal Care and Use Committee of New York University.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

View Full Text

Statistics from Altmetric.com

Footnotes

  • RL and YC contributed equally.

  • Handling editor Josef S Smolen

  • Contributors RL and YC designed and performed experiments, collected and analysed data, and cowrote the paper. YC participated in the design of the experiments and analysis of the data, particularly the identification and characterisation of the drug target. WF, SW, XZ, AH, JL, L. Zhang, CW, CZ and YB assisted with experiments, and collected and analysed data. ZL and Z-SC performed the IFD and MD simulations, and also assisted in editing the manuscript. GX assisted in analysing the data and editing the manuscript. CL designed and supervised this study, analysed data, and wrote and edited the manuscript.

  • Funding This work was supported partly by NIH research grants R01AR062207, R01AR061484, R01NS103931 and a DOD research grant W81XWH-16-1-0482.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Ethics approval All animal studies were performed in accordance with institutional guidelines and with approval from the Institutional Animal Care and Use Committee of New York University.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.